131 related articles for article (PubMed ID: 37192696)
1. Growth differentiation factor-15 and prediction of cancer-associated thrombosis and mortality: a prospective cohort study.
Nopp S; Moik F; Kraler S; Englisch C; Preusser M; von Eckardstein A; Pabinger I; Lüscher TF; Ay C
J Thromb Haemost; 2023 Sep; 21(9):2461-2472. PubMed ID: 37192696
[TBL] [Abstract][Full Text] [Related]
2. Risk factors of arterial thrombotic events after unprovoked venous thromboembolism, and after cancer associated venous thromboembolism: A prospective cohort study.
Noumegni SR; Didier R; Mansourati V; Tromeur C; Le Moigne E; Hoffmann C; Nasr B; Gentric JC; Guegan M; Poulhazan E; Lacut K; Bressollette L; Le Mao R; Couturaud F
Thromb Res; 2022 Jun; 214():93-105. PubMed ID: 35525202
[TBL] [Abstract][Full Text] [Related]
3. Growth differentiation factor-15 predicts major bleeding, major adverse cardiac events and mortality in patients with end-stage kidney disease on haemodialysis: findings from the VIVALDI study.
Nopp S; Königsbrügge O; Schmaldienst S; Klauser-Braun R; Lorenz M; Pabinger I; Säemann M; Ay C
Nephrol Dial Transplant; 2023 Jul; 38(8):1836-1847. PubMed ID: 36472548
[TBL] [Abstract][Full Text] [Related]
4. Plasma levels of growth differentiation factor 15 are associated with future risk of venous thromboembolism.
Hansen ES; Hindberg K; Latysheva N; Aukrust P; Ueland T; Hansen JB; Brækkan SK; Morelli VM;
Blood; 2020 Oct; 136(16):1863-1870. PubMed ID: 32645137
[TBL] [Abstract][Full Text] [Related]
5. Antithrombin Activity and Association with Risk of Thrombosis and Mortality in Patients with Cancer.
Englisch C; Königsbrügge O; Nopp S; Moik F; Quehenberger P; Preusser M; Pabinger I; Ay C
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555414
[TBL] [Abstract][Full Text] [Related]
6. Soluble Vascular Endothelial Growth Factor (sVEGF) and the Risk of Venous Thromboembolism in Patients with Cancer: Results from the Vienna Cancer and Thrombosis Study (CATS).
Posch F; Thaler J; Zlabinger GJ; Königsbrügge O; Koder S; Zielinski C; Pabinger I; Ay C
Clin Cancer Res; 2016 Jan; 22(1):200-6. PubMed ID: 26302981
[TBL] [Abstract][Full Text] [Related]
7. Tissue factor pathway inhibitor is associated with risk of venous thromboembolism and all-cause mortality in patients with cancer.
Englisch C; Moik F; Thaler J; Koder S; Mackman N; Preusser M; Pabinger I; Ay C
Haematologica; 2024 Apr; 109(4):1128-1136. PubMed ID: 37822244
[TBL] [Abstract][Full Text] [Related]
8. Utility of the Khorana and the new-Vienna CATS prediction scores in cancer patients of the HYPERCAN cohort.
Verzeroli C; Giaccherini C; Russo L; Bolognini S; Gamba S; Tartari CJ; Schieppati F; Ticozzi C; Vignoli A; Masci G; Sarmiento R; Spinelli D; Malighetti P; Tondini C; Petrelli F; Giuliani F; D'Alessio A; Gasparini G; Minelli M; De Braud F; Santoro A; Labianca R; Marchetti M; Falanga A;
J Thromb Haemost; 2023 Jul; 21(7):1869-1881. PubMed ID: 37054917
[TBL] [Abstract][Full Text] [Related]
9. Red cell distribution width and other red blood cell parameters in patients with cancer: association with risk of venous thromboembolism and mortality.
Riedl J; Posch F; Königsbrügge O; Lötsch F; Reitter EM; Eigenbauer E; Marosi C; Schwarzinger I; Zielinski C; Pabinger I; Ay C
PLoS One; 2014; 9(10):e111440. PubMed ID: 25347577
[TBL] [Abstract][Full Text] [Related]
10. Growth Differentiation Factor-15, High-Sensitivity Cardiac Troponin T, and N-Terminal pro-B-type Natriuretic Peptide for Predicting Risk of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy.
Roy DC; Wang TF; Mallick R; Carrier M; Mollanji E; Liu P; Zhang L; Hawken S; Wells P
Thromb Haemost; 2022 Jul; 122(7):1169-1176. PubMed ID: 35263789
[TBL] [Abstract][Full Text] [Related]
11. Association Between Decreased Serum Albumin With Risk of Venous Thromboembolism and Mortality in Cancer Patients.
Königsbrügge O; Posch F; Riedl J; Reitter EM; Zielinski C; Pabinger I; Ay C
Oncologist; 2016 Feb; 21(2):252-7. PubMed ID: 26764252
[TBL] [Abstract][Full Text] [Related]
12. Ex vivo properties of plasma clot formation and lysis in patients with cancer at risk for venous thromboembolism, arterial thrombosis, and death.
Posch F; Hofer S; Thaler J; Hell L; Königsbrügge O; Grilz E; Mauracher LM; Gebhart J; Marosi C; Jilma B; Pabinger I; Ay C
Transl Res; 2020 Jan; 215():41-56. PubMed ID: 31525325
[TBL] [Abstract][Full Text] [Related]
13. Incidence, risk factors, and outcomes of venous and arterial thromboembolism in immune checkpoint inhibitor therapy.
Moik F; Chan WE; Wiedemann S; Hoeller C; Tuchmann F; Aretin MB; Fuereder T; Zöchbauer-Müller S; Preusser M; Pabinger I; Ay C
Blood; 2021 Mar; 137(12):1669-1678. PubMed ID: 33067632
[TBL] [Abstract][Full Text] [Related]
14. Hemostatic Biomarkers and Venous Thromboembolism Are Associated With Mortality and Response to Chemotherapy in Patients With Pancreatic Cancer.
Moik F; Prager G; Thaler J; Posch F; Wiedemann S; Schramm T; Englisch C; Mackman N; Pabinger I; Ay C
Arterioscler Thromb Vasc Biol; 2021 Nov; 41(11):2837-2847. PubMed ID: 34470475
[TBL] [Abstract][Full Text] [Related]
15. Impact of antiphospholipid antibodies on thrombotic events in ambulatory cancer patients.
Kansuttiviwat C; Niprapan P; Tantiworawit A; Norasetthada L; Rattarittamrong E; Rattanathammethee T; Hantrakool S; Piriyakhuntorn P; Punnachet T; Hantrakun N; Chai-Adisaksopha C
PLoS One; 2023; 18(1):e0279450. PubMed ID: 36662720
[TBL] [Abstract][Full Text] [Related]
16. Polygenic risk scores for prediction of cancer-associated venous thromboembolism in the UK Biobank cohort study.
Guman NAM; Mulder FI; Ferwerda B; Zwinderman AH; Kamphuisen PW; Büller HR; van Es N
J Thromb Haemost; 2023 Nov; 21(11):3175-3183. PubMed ID: 37481074
[TBL] [Abstract][Full Text] [Related]
17. Impact of ALK Rearrangement on Venous and Arterial Thrombotic Risk in NSCLC.
Al-Samkari H; Leiva O; Dagogo-Jack I; Shaw A; Lennerz J; Iafrate AJ; Bendapudi PK; Connors JM
J Thorac Oncol; 2020 Sep; 15(9):1497-1506. PubMed ID: 32437899
[TBL] [Abstract][Full Text] [Related]
18. Association of Platelet-to-Lymphocyte Ratio and Neutrophil-to-Lymphocyte Ratio with the Risk of Thromboembolism and Mortality in Patients with Cancer.
Grilz E; Posch F; Königsbrügge O; Schwarzinger I; Lang IM; Marosi C; Pabinger I; Ay C
Thromb Haemost; 2018 Nov; 118(11):1875-1884. PubMed ID: 30296815
[TBL] [Abstract][Full Text] [Related]
19. Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Riedl JM; Schwarzenbacher E; Moik F; Horvath L; Gantschnigg A; Renneberg F; Posch F; Barth DA; Stotz M; Pichler M; Hatzl S; Fandler-Höfler S; Gressenberger P; Gary T; Jost PJ; Greil R; Ay C; Djanani A; Gerger A; Schlick K
Thromb Haemost; 2022 Apr; 122(4):633-645. PubMed ID: 34255340
[TBL] [Abstract][Full Text] [Related]
20. A Clinical-Genetic Risk Score for Predicting Cancer-Associated Venous Thromboembolism: A Development and Validation Study Involving Two Independent Prospective Cohorts.
Muñoz A; Ay C; Grilz E; López S; Font C; Pachón V; Castellón V; Martínez-Marín V; Salgado M; Martínez E; Calzas J; Ortega L; Rupérez A; Salas E; Pabinger I; Soria JM
J Clin Oncol; 2023 Jun; 41(16):2911-2925. PubMed ID: 36730884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
